Michael Higgins, Voyager interim CEO
Novartis takes a gamble on Voyager's new AAV tech, inks $1.7B gene therapy discovery pact
Whatever Voyager is coming up with on its new gene therapy platform, Novartis wants a piece of it.
Voyager, which pivoted back into discovery last …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
